Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
Sameer A. Greenall, Shengnan C Chen, Gordon Alton…·Rohan G. T. Lowe
This study shows that CT-179, an OLIG2 inhibitor, reduces glioblastoma growth and enhances chemoradiotherapy efficacy in preclinical models.